AxoGen, Inc. (NASDAQ:AXGN) Director Sells $100,100.00 in Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the sale, the director now directly owns 97,899 shares of the company’s stock, valued at approximately $1,959,937.98. This represents a 4.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

AxoGen Stock Performance

NASDAQ:AXGN opened at $17.73 on Friday. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $21.00. The firm’s fifty day simple moving average is $17.90 and its 200 day simple moving average is $15.26. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $786.22 million, a PE ratio of -55.41 and a beta of 1.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AXGN. Quest Partners LLC boosted its holdings in AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the period. R Squared Ltd bought a new stake in AxoGen in the 4th quarter valued at $30,000. US Bancorp DE bought a new stake in AxoGen in the 4th quarter valued at $30,000. State of Wyoming bought a new stake in AxoGen in the 4th quarter valued at $31,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in AxoGen in the 4th quarter valued at $93,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Canaccord Genuity Group upped their price target on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $24.00 price objective on shares of AxoGen in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $20.75.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.